Loading
HMPL-453 is an experimental small-molecule drug from Hutchmed in phase 3 trials for biliary tract cancer, aimed at FGFR2.
HMPL-453 is a small-molecule drug developed by Hutchmed. Its target is FGFR2 (the sponsor names FGFR2). ClinicalTrials.gov describes the intervention as: Cohort\_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort\_2, Cohort\_3 and Cohort\_4:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04353375 (HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma), in biliary tract cancer. The largest, NCT04353375, plans to enrol 235 participants with primary completion expected 2028-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Small-molecule drug directed at FGFR2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to FGFR2.
1.HMPL-453 slips into a pocket on FGFR2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HMPL-453" OR ABSTRACT:"HMPL-453") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HMPL-453, not a curated reading list.
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares FGFR2, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares FGFR2 and the tag pipeline.
Shares Hutchmed and the tag pipeline.
Shares Hutchmed and the tag pipeline.